AstraZeneca Results Presentation Deck
Emerging Markets
Total revenue $7.5bn, excluding COVID-19 vaccine revenue
Emerging markets +10%¹
China +8%; Ex-China EMs +14%¹
$m
3,500
3,000
2,500
2,000
1,500
1,000
500
0
Q3 Q4
2019
Q1
Q2
Q3 Q4 Q1
2020
China Ex-China EMS COVID-19 vaccine sales
Q2
2021
Q3
0
Diversified growth across geographies
Addressing global unmet medical need
Oncology $2.4bn +4%: Tagrisso $1bn, up 1% due to March
2021 1st-line NRDL inclusion impact in China
CVRM $2.9bn, +14%: strong growth for Forxiga ($877m, +74%)
as a result of increased demand in China and improved patient
access in Latin America. Continued growth for roxadustat in
China, approved in South Korea in Q3
Respiratory & Immunology +17%: Pulmicort ($578m, +13%)
saw slight COVID-19 impact recovery ahead of VBP
implementation in October; Symbicort growth ($457m, +4%)
24 1. Growth number calculated excluding revenue of the COVID-19 vaccine. Growth including the COVID-19 vaccine is as follows: Emerging Market total revenue growth 28%, China +8%; Other EMS +60%. Roxadustat is being
commercialised in collaboration with FibroGen Inc.
BView entire presentation